Alejandro Recio Boiles, MD
Hematology-Oncology · Tucson, AZNPI 1104266964
Payments from drug & device makers
Across 541 payments — averaging $4586.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$955K
- Merck$827K
- E.r. Squibb & Sons, L.L.C.$199K
- Eli Lilly$173K
- AbbVie$98K
- Pfizer$83K
- plus $147K from 23 others
Across 1 payment — averaging $2600.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 259 | $954,951 |
| Merck | 124 | $826,850 |
| E.r. Squibb & Sons, L.L.C. | 13 | $198,608 |
| Eli Lilly | 14 | $173,230 |
| AbbVie | 30 | $98,070 |
| Pfizer | 13 | $82,577 |
| Genentech, Inc. | 13 | $50,541 |
| Boehringer Ingelheim | 9 | $48,295 |
| Bayer | 18 | $37,903 |
| Immunomedics, Inc. | 4 | $4,250 |
| Johnson & Johnson | 3 | $1,479 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 11 | $1,106 |
| Janssen Global Services, LLC | 3 | $1,050 |
| Boehringer Ingelheim International GmbH | 1 | $785 |
| Astellas Pharma US Inc | 6 | $226 |
| Sanofi-aventis U.S. LLC | 2 | $189 |
| Sumitomo Pharma America, Inc. | 2 | $189 |
| Fennec Pharmaceuticals, Inc. | 1 | $152 |
| Incyte Corporation | 3 | $141 |
| Rigel Pharmaceuticals, Inc. | 1 | $123 |
| Jazz Pharmaceuticals Inc. | 1 | $122 |
| Sanofi | 3 | $120 |
| Exelixis Inc. | 1 | $112 |
| Caris MPI, Inc. | 1 | $73 |
| Myovant Sciences Inc. | 1 | $60 |
| AVEO Pharmaceuticals, Inc. | 1 | $28 |
| Bristol Myers Squibb | 1 | $22 |
| Genentech USA, Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $18 |
How this compares
Too few hematology-oncology providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology-oncology in Tucson
- Madappa KundrandaGilbert$2.8M
- Amol RakkarGlendale$919K
- Navjeet GandhokPeoria$19K
- Valerie IsraelLake Havasu City$4K
- James ChoiGlendale$4K
- Madhuri KadiyalaChandler$865
- Srivyshnavi NarraSun City$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.